Cambridge Healthtech Institute’s Inaugural

Drug Discovery Technologies

Enabling Disruptive Innovation

June 3-4, 2020


High costs and long timelines in biopharma R&D emphasize the need for novel technologies that enable new therapeutic platforms and a better understanding of disease. CHI’s Inaugural Drug Discovery Technologies conference is designed as a comprehensive overview of current and emerging technologies and their providers. Each speaker will address a certain technology and its scientific implications in drug discovery and development programs.

Final Agenda

Wednesday, June 3

7:30 am Registration Open and Morning Coffee

10:15 Coffee Break in the Exhibit Hall with Poster Viewing

STATE-OF-THE-ART DISEASE MODELING

10:55 Chairperson Remarks

11:00 Applications of Organoid Technology

Sina Mohammadi, PhD, Associate Principal Scientist, Merck & Co., Inc.

11:15 CRISPR in Disease Modeling

Danilo Maddalo, PhD, Lab Head, ONC Pharmacology, Novartis Institutes for BioMedical Research, Novartis Pharma AG

11:30 3D Models of Brain Cancer for Precision Medicine Therapeutic Profiling

Virneliz Fernández-Vega, Scientific Associate, Molecular Medicine, Scripps Florida

11:45 Human Heart Slices as a Reliable Platform for Predicting Cardiotoxicity

Tamer Mohamed, PhD, Assistant Professor of Medicine, Institute of Molecular Cardiology, University of Louisville

12:00 pm Animal Models of Cancer

Viswanathan Muthusamy, PhD, Research Scientist; Executive Director, Center for Precision Cancer Modeling, Yale School of Medicine

12:20 Tissue-Specific Extracellular Matrix Substrates to Accelerate Drug DevelopmentXylyx

Evelyn Aranda, Senior Research Scientist, Xylyx Bio, Inc.

Introducing a standardized, commercial 3D cell culture platform for cancer research and discussing how this platform can reduce the dependence on animal models, and enable more relevant scientific results leading to improved drug discovery process. 

12:35 Enjoy Lunch on Your Own


PLENARY KEYNOTE SESSION

1:45 - 3:15

Lgr5 Stem Cell-Based Organoids in Human Disease

Hans Clevers, MD, CSO, Director of Research, Princess Máxima Center for Pediatric Oncology, University Medical Center Utrecht; Principal Investigator, Hubrecht Institute for Developmental Biology and Stem Cell Research

Systematically Drugging Ras

Stephen Fesik, PhD, Professor of Biochemistry, Pharmacology, and

Chemistry, Orrin H. Ingram II Chair in Cancer Research, Vanderbilt

University School of Medicine

3:15 Refreshment Break in the Exhibit Hall with Poster Viewing

Selected Poster Presentations

4:00 Chairperson Remarks

4:10 Selected Poster Presentations; 10 minutes each

4:40 Voting and Best Poster Award

5:05 Find your Table, Meet your Moderator

5:10 Roundtable Breakout Discussions

5:45 Reception in the Exhibit Hall with Poster Viewing

6:00 Innovation Station

6:45 Close of Day

Thursday, June 4

8:00 am Registration Open


PLENARY KEYNOTE SESSION

8:30 - 9:40 pm

Applications of Artificial Intelligence in Drug Discovery – Separating Hype from Utility

Patrick Walters, PhD, Senior Vice President, Computation, Relay Therapeutics

9:40 Coffee Break in the Exhibit Hall with Poster Viewing

DRUG TARGET SCREENING AND VALIDATION TECHNOLOGIES

10:25 Chairperson’s Remarks

10:30 Ultra-High-Pressure Liquid Chromatography in Pharmaceutical Analysis: Benefits and Impact

Michael Dong, PhD, Principal Consultant, MWD Consulting

10:45 Automation Meets Cell Separation: Primary Cell Isolation for Immuno-oncology Assays

Lotta Raety, Group Leader, Product Manager, Cell Separation, Global Marketing, Miltenyi Biotec B.V. & Co. KG

11:00 Accelerating Drug Discovery and Development with an Emerging, Customizable Mode of Microfluidics

Anita Rogacs, PhD, Head of Life Sciences Strategy and R&D, HP Labs

11:15 DNA-Encoded Library Technology for Target-based Screening

Svetlana Belyanskaya, PhD, Encoded Library Technologies, R&D Platform Technology & Science, GSK Boston

11:30 Lipidomics for Pharmacodynamics: How Shotgun Lipidomics Unraveled the Mode-of-Action of the Anti-Tumor Drug Minerval®

Christian Klose, PhD, Head, R&D, Lipotype GmbH

11:45 The State of the Art in Highly Multiplexed Multi in situ OMICs

Richie Kohman, PhD, Senior Research Scientist and Lead, Synthetic Biology Platform, Wyss Institute for Biologically Inspired Engineering, Harvard University

12:00 pm Women in Pharma Luncheon Panel Discussion (Sponsorship Opportunity Available)

1:00 Dessert and Coffee Break in the Exhibit Hall with Poster Viewing

1:45 End of Drug Discovery Technologies Track

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean




June 2-4

Accelerating Target Discovery

Expanding Chemical & Druggable Space

New Small Molecule Drug Targets

Emerging Indications and Modalities

Immuno-Oncology Advances

Disease Modeling

Preclinical Strategies, Models & Tools in Oncology

Advances in Drug Metabolism & Safety Testing

Immuno-Oncology Biomarkers

Clinical and Translational Biomarkers

AI for Drug Discovery and Development

June 3-4

Drug Discovery Technologies